What is 
Endura-KT™ is a sterile, preservative-free compounded local anesthetic preparation containing tetracaine 0.2%, lidocaine 0.4% and epinephrine 1:250,000 after preparation. It is designed to support clinicians in managing procedural and post-operative discomfort.
Healthcare Professionals
Explore product, clinical, safety, and handling information.
Patients & Caregivers
Understand Endura-KT, compounded medications, and what to discuss with your provider
Endura-KT is a compounded drug preparation and is not FDA approved. FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
Why was Developed?
The story behind Endura-KT
The Role of 503B
The 503B pathway allows qualifying outsourcing facilities to compound (manufacture) medications for healthcare providers, including office stock, subject to the conditions in federal law. It provides the manufacturing framework for Endura-KT today. It does not mean that Endura-KT is FDA approved or that FDA has evaluated the product’s safety or effectiveness.
The Development Objective
The team focused on a sterile, preservative-free formulation that combined tetracaine, lidocaine and epinephrine at dilute concentrations. Their objective was to create an additional local anesthetic option for licensed healthcare professionals to evaluate within their own clinical judgment and protocols.
That work became Endura-KT: a compounded formulation intended for professional use in procedural settings.
The Mission
Our mission is to expand clinician access to thoughtfully developed, opioid-free local anesthetic options for procedural and post-operative care. Through responsible education, consistent product quality and clinician-directed use, we aim to support informed clinical decision-making and a better patient-care experience.
The Mission
Our mission is to expand clinician access to thoughtfully developed, opioid-free local anesthetic options for procedural and post-operative care. Through responsible education, consistent product quality and clinician-directed use, we aim to support informed clinical decision-making and a better patient-care experience.
The Difference
A New procedural approach to post-procedural pain
Opioid-free formulation containing tetracaine, lidocaine and epinephrine
Sterile and preservative-free preparation
Balanced, dilute concentrations intended to permit adequate volume administration at the procedural site
Multiple vial sizes to support different anticipated procedural volumes and established clinical workflows
in Dentistry
Supporting Dental Professionals with Advanced Compounded Solutions
Ventis Pharma is dedicated to providing healthcare professionals with high-quality compounded preparations produced under Section 503B of the Federal Food, Drug, and Cosmetic Act. Our Dental Division focuses on offering products that meet the clinical needs of oral and maxillofacial practitioners seeking consistent quality and dependable performance.
The Standards Behind
What is a 503B outsourcing facility?
a 503B outsourcing facility is an FDA-registered facility that compounds medications under federal quality and manufacturing requirements. These facilities are subject to FDA oversight and cGMP standards designed to support the quality, consistency, and safety of compounded preparations.
Manufactured with Defined Quality Controls
Endura-KT is compounded by OurPharma, an FDA-registered 503B outsourcing facility subject to current Good Manufacturing Practice requirements and risk-based FDA inspection. OurPharma’s quality systems include environmental monitoring, vendor qualification, visual inspection, third-party release testing and documented lot-release review.
FDA registration and inspection requirements
Outsourcing facilities are subject to FDA inspections on a risk-based schedule.
cGMP manufacturing standards
Safety and potency testing
What offers
A combination of three well-established anesthetic ingredients provided in a sterile, ready-to-use format
A formulation prepared in accordance with FDA 503B Outsourcing Facility standards, including cGMP manufacturing.
Availability in multiple vial sizes to support procedural flexibility across various clinical settings
Designed for use by licenses physicians who determine if a compounded preparation is appropriate for their patients.
A Focus on Quality, Safety, and Compliance
Our 503B outsourcing partner follows:
- cGMP standards
- Routine FDA, State Board of Pharmacy and DEA inspections
- Batch-level sterility, potency, and endotoxin testing
- Documented lot release procedures
We are committed to ensuring that clinicians have access to accurate, compliant, and transparent information about the preparation they choose to use.
Supporting Clinician Decisions Through Education
Endura-KT is not FDA-approved; as a 503B-compounded preparation, it is intended to address clinical situations where healthcare professionals determine that available FDA-approved products may not meet specific patient or procedural needs.
Ventis Pharma provides educational resources only, and all clinical decisions—including dosing, use protocols, and patient-specific risk assessments—are made solely by the treating provider.
Clinical / Professional Applications
Hospital Surgery / Perioperative Teams
Endura-KT is a sterile 503B-compounded anesthetic preparation that may be incorporated into perioperative workflows at the clinician’s discretion. Surgical teams may consider compounded anesthetic preparations in cases where FDA-approved alternatives do not meet patient-specific or procedural requirements.
Dentists
Endura-KT™ is a sterile, preservative-free local anesthetic solution compounded under FDA 503B Outsourcing Facility standards. It contains lidocaine, tetracaine, and epinephrine in a formulation designed to support clinicians in managing procedural and post-operative discomfort.
Anesthesia
Endura-KT is a 503B-compounded combination of tetracaine, lidocaine, and epinephrine formulated for use by licensed anesthesia providers. It may be chosen when a clinician determines that a compounded anesthetic preparation aligns with a particular block technique, workflow, or patient presentation.
Emergency Medicine & Trauma
Emergency clinicians may use Endura-KT—a 503B-compounded anesthetic formulation—when they determine that a compounded preparation supports their approach to procedural analgesia, laceration management, or other emergent interventions requiring localized anesthesia.
Ambulatory Surgery Centers (ASC)
Endura-KT is a sterile 503B-compounded anesthetic option that ASC providers may select when they determine that a ready-to-use compounded formulation supports their procedural environment, workflow efficiency, or individualized patient needs.
Surgical Oncology
Oncology surgical teams may choose Endura-KT, a 503B-compounded anesthetic preparation, when a clinician determinesthat a tailored anesthetic formulation supports the requirements of tumor-related or complex surgical interventions.
OB-GYN Surgery
OB-GYN providers may incorporate Endura-KT, when appropriate, as a 503B-compounded anesthetic preparation in procedures requiring localized or adjunctive anesthesia, based on clinician judgement regarding patient needs and procedural goals.
Plastic & Reconstructive Surgery
Licensed plastic surgeons may use Endura-KT—a 503B-compounded tetracaine/lidocaine/epinephrine formulation—when determining their anesthetic approach for reconstructive or aesthetic procedures requiring localized anesthesia.
Wound Care / Limb Salvage / Chronic Ulcer Procedures
Wound care specialists may elect to use Endura-KT as a 503B-compounded anesthetic preparation when localized anesthesia is needed for debridement or procedural interventions and when clinicians determine that a compounded option supports patient-specific needs.
Podiatry
Podiatric surgeons may consider Endura-KT, a 503B-compounded anesthetic preparation, when determining localized anesthesia strategies for foot and ankle procedures based on patient-specific or procedural-specific needs.
Proctology / Colorectal Surgery
Colorectal and proctologic surgeons may incorporate Endura-KT—when deemed appropriate by the clinician—as a 503B-compounded anesthetic preparation to support localized anesthesia for office-based or surgical interventions.
Ready to take the next step?
Have questions about Endura-KT? Explore the details or connect with our team to learn more.
ASRA and COA Conferences
Ventis Pharma's success as ASRA and COA Conferences: A glimpse into a bright future. We are thrilled to share...
Trusted partner
Ventis Pharma is dedicated to providing healthcare professionals with high-quality compounded preparations produced under Section 503B of the Federal Food, Drug, and Cosmetic Act.
Supporting Dental Professionals with Advanced Compounded Solutions
Our Dental Division focuses on offering products that meet the clinical needs of oral and maxillofacial practitioners seeking consistent quality and dependable performance.
Endura-KT™ is a 503B compounded preparation and has not been evaluated or approved by the FDA. Educational content is provided solely for licensed healthcare professionals to support informed clinical decision-making.
No safety or efficacy claims are being made.
This website is designed for licensed healthcare professionals involved in perioperative care, procedural anesthesia, surgery, dentistry, emergency medicine, and other clinical specialties.